About: Chloroquine or Hydroxychloroquine for COVID‐19: Is Cardiotoxicity a Concern?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine or Hydroxychloroquine for COVID‐19: Is Cardiotoxicity a Concern? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chloroquine or Hydroxychloroquine for COVID‐19: Is Cardiotoxicity a Concern?
Creator	Kamp, Timothy Hamdan, Mohamed January, Craig
Source	Medline; PMC
abstract	The SARS-Cov-2 viral pandemic causing COVID-19 disease begs for rapid and innovative treatments. In addition to flu-like respiratory symptoms, acute cardiac manifestations include cardiac injury, shock and arrhythmia. Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, sometimes co-administered with azithromycin. Chloroquine and hydroxychloroquine were developed in the World War II era for treatment and prophylaxis of malaria, long before modern drug safety surveillance programs. Clinically they can prolong the QT interval to potentially initiate ventricular arrhythmias including torsades de pointes, and also cause QRS widening. Chloroquine interacts with multiple cardiac ion channels including the hERG potassium channel that is essential for normal electrical activity in the heart. A reduction in hERG channel potassium current is the principle cause of drug-induced long QT syndrome. Azithromycin also can cause modest QT interval prolongation, but not through potent hERG channel blockade, rather when used chronically through an increase in peak and late cardiac sodium current to cause potential loading of cardiomyocytes with sodium and calcium to produce calcium overload. How should we proceed with the use of chloroquine and hydroxychloroquine, potentially combined with azithromycin, for COVID-19 given that these agents bring some cardiac toxicity risk and their mechanisms for cardiac toxicity may not be the same? Is combining different and potentially additive mechanisms of cardiotoxicity wise? How great the risk is relative to the benefit in critically ill COVID-19 patients will need to await the outcome of ongoing, controlled clinical trials.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1161/jaha.120.016887
bibo:pmid	32463308
has license	cc-by-nc-nd
sha1sum (hex)	4401574a36a5a106f9e70833bb66ee12a79a1528
schema:url	https://doi.org/10.1161/jaha.120.016887
resource representing a document's title	Chloroquine or Hydroxychloroquine for COVID‐19: Is Cardiotoxicity a Concern?
has PubMed Central identifier	PMC7429067
has PubMed identifier	32463308
schema:publication	J Am Heart Assoc
resource representing a document's body	covid:4401574a36a5a106f9e70833bb66ee12a79a1528#body_text
is schema:about of	named entity 'Chloroquine' named entity 'arrhythmia' named entity 'comorbidities' named entity 'cytokine storm' named entity 'channel blocker' named entity 'potassium channels' named entity 'calcium' named entity 'Concern' named entity 'prolong the QT interval' named entity 'potassium' named entity 'binding site' named entity 'COVID' named entity 'telemetry' named entity 'azithromycin' named entity 'prophylaxis' named entity 'sodium current' named entity 'electrophysiological properties' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'clinical trials' named entity 'Chloroquine' named entity 'virologists' named entity 'proarrhythmia' named entity 'clinical trials' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'clinical trials' named entity 'arrhythmias' named entity 'COVID' named entity 'ventricular arrhythmias' named entity 'safety profile' named entity 'myocardium' named entity 'QRS' named entity 'repolarizing' named entity 'cardiac conduction' named entity 'Azithromycin' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'COVID' named entity 'conduction abnormalities' named entity 'cardiovascular' named entity 'electrolyte' named entity 'China' named entity 'chloroquine' named entity 'COVID' named entity 'rheumatological' named entity 'United States' named entity 'randomized clinical trials' named entity 'active metabolites' named entity 'chloroquine' named entity 'drug-induced' named entity 'off-label' named entity 'torsades de pointes' named entity 'chloroquine' named entity 'macrolide antibiotic' named entity 'cardiac complications' named entity 'chloroquine' named entity 'sodium' named entity 'hydroxychloroquine' named entity 'drug-induced' named entity 'controlled clinical trials' named entity 'off-label treatment' named entity 'cardiovascular' named entity 'cardiotoxicity' named entity 'torsades de pointes' named entity 'hydroxychloroquine' named entity 'viral pandemic' named entity 'rectifier' named entity 'cardiac events' named entity 'prophylaxis' named entity 'overdose' named entity 'therapeutic window' named entity 'malaria' named entity 'World War II' named entity 'ECG' named entity 'long QT syndrome' named entity 'QT interval' named entity 'hydroxychloroquine' named entity 'prolonged QT interval' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software